Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EXACT Therapeutics AS ( (DE:56F) ) has shared an update.
EXACT Therapeutics AS has been granted a patent in Japan for its Acoustic Cluster Therapy (ACT®) for treating pancreatic cancer, securing patent protection until 2040. This development is significant as Japan is a major market, and it aligns with EXACT’s ongoing efforts in their Phase 2 ENACT trial, which aims to advance the treatment of pancreatic cancer.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company specializing in targeted drug delivery in oncology through the use of ultrasound and microbubbles. Their proprietary Acoustic Cluster Therapy (ACT®) is designed to enhance the delivery of therapeutic agents and is being tested in a Phase 2 trial for pancreatic cancer. The company is listed on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 7,451
Current Market Cap: NOK189.8M
For detailed information about 56F stock, go to TipRanks’ Stock Analysis page.